Nurix Therapeutics (NRIX.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Nov7

Oppenheimer Reiterates Buy Rating on Nurix Therapeutics

19:56

Nov4

Gil Blum gives Nurix Therapeutics' bexodeg a buy rating

10:16

Oct23

Nurix Therapeutics Maintained at Hold Rating

08:47

Oct22

Nurix Therapeutics Announces Registered Offering to Raise $250 Million

11:21

Nurix Therapeutics Launches Clinical Trial for Chronic Lymphocytic Leukemia

10:02

Oct20

Nurix Therapeutics to Launch a Key Trial for Bexobrutideg

09:42

Schedules & Filings

Schedules

Filings

Oct9

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 7.894 M, Net Income -86.42 M, EPS -1.0268

Jul9

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 44.06 M, Net Income -43.46 M, EPS -0.5181

Apr8

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 18.45 M, Net Income -56.35 M, EPS -0.6743

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change